ARTICLE | Company News
Diaxonhit, Felicitex Therapeutics deal
June 22, 2015 7:00 AM UTC
Diaxonhit granted Felicitex exclusive, worldwide rights to develop and commercialize preclinical small molecule compounds targeting dual-specificity tyrosine-(Y)-phosphorylation regulated kinase (DYRK...